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SUMMARY
Immunotherapy has yielded impressive results, but only for a minority of patients
with cancer. Therefore, new approaches that potentiate immunotherapy are a
pressing medical need. Ferroptosis is a newly described type of programmed
cell death driven by iron-dependent phospholipid peroxidation via Fenton chem-
istry. Here, we developed iron oxide-loaded nanovaccines (IONVs), which, chem-
ically programmed to integrate iron catalysis, drug delivery, and tracking exploit-
ing the characteristics of the tumor microenvironment (TME), improves
immunotherapy and activation of ferroptosis. The IONVs trigger danger signals
and use molecular disassembly and reversible covalent bonds for targeted anti-
gen delivery and improved immunostimulatory capacity and catalytic iron for tar-
geting tumor cell ferroptosis. IONV- and antibody-mediated TME modulation in-
terfaced with imaging was important toward achieving complete eradication of
aggressive and established tumors, eliciting long-lived protective antitumor im-
munity with no toxicities. This work establishes the feasibility of using nanopar-
ticle iron catalytic activity as a versatile and effective feature for enhancing immu-
notherapy.
INTRODUCTION
It is becoming apparent that the immune system can be harnessed to treat cancer. One of the most
promising new approaches is based on immune checkpoint inhibitors (ICIs), which re-invigorate the ca-
pacity of tumor antigen-specific T cells to attack the cancer (Wei et al., 2018). This immunotherapy has
enabled some patients to produce an effective and durable antitumor response. However, the propor-
tion of patients responding to single ICIs remains low (<20%) (Shields et al., 2017; Chen and Han, 2015).
Despite efforts to develop combinatorial approaches that increase response rates, studies show minimal
improvements in patient survival and/or greater toxicity, usually as a result of targeting redundant im-
mune pathways (Moslehi et al., 2018; Messenheimer et al., 2017). Targeting immune checkpoints har-
nesses a pre-existing (ineffective) immune response of so-called immune ‘‘hot’’ tumors (Galon and Bruni,
2019) and is hampered by immune-related adverse effects (Friedman et al., 2016) and acquired drug
resistance (Jenkins et al., 2018). Therefore, attractive strategies to improve the therapeutic index of ICI
are based on the development of immunotherapy drug delivery technologies, and targeting non-redun-
dant additional pathways, such as metabolic features of cancer, through combinatorial approaches (Riley
et al., 2019; Doll et al., 2019).
Advancesmade in the understanding of the biology of cancer, biomedical engineering, and nanochemistry
have enabled innovative treatment strategies, which when investigated in combination with immuno-
therapy show synergistic therapeutic effects in mouse models of cancer, but obstacles to their clinical trans-
lation remain. Combination with nanoparticle-enabled photodynamic therapy (PDT) (Ni et al., 2018) is
limited by the light penetration depth, oxygen reliance, and systemic toxicity due to off-site drug accumu-
lation (Lucky et al., 2015), whereas use of high-intensity focused ultrasound (HIFU) (Eranki et al., 2019) is also
unsuitable for deep-seated tumors owing to attenuation of the ultrasound waves in deep tissue. Immuno-
therapy enhancement by photothermal ablation (PTA) and by magnetic hyperthermia (MHT) (Chao et al.,
2019) require high local nanoparticle concentrations, which can cause severe damages to normal tissue in
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the tumor margins and induce tumor metastasis. Although iron oxide nanoparticle (IONP)-enabled ICI de-
livery applying external magnetic field has been reported in mice (Chiang et al., 2018), it is not currently
feasible in targeting deep tumor tissue of human patients partly owing to lack of suitable magnetic systems
(Shapiro et al., 2015). Consequently, there is an urgent need for developing approaches that address these
challenges. Growing evidence implies that the tumor microenvironment (TME), which poses a significant
obstacle to these approaches, may be targeted and harnessed to obtain substantial therapeutic benefits
(Pitt et al., 2016; Anderson et al., 2017).
The immune component of the TME contains CD4+ and CD8+ T cells (regulatory T cells [Tregs] and ex-
hausted effector T cells) and tolerogenic dendritic cells (DCs) and tumor-associated macrophages (Shiao
et al., 2011; Gajewski et al., 2013). Intracellular communication in the TME is driven by a complex and dy-
namic network of signaling molecules such as cytokines and chemokines against a backdrop of specific
metabolic alterations (hypoxia, low pH, nutrient deprivation, high content of H2O2, etc.). These features
result in cancer cell metabolic reprogramming (Ward and Thompson, 2012) and an intrinsic vulnerability
of cancer cells to a newly described form of regulated cell death termed ferroptosis (Yang and Stockwell,
2016). Ferroptosis, induced by oxidative stress and characterized by iron-dependent phospholipid perox-
idation via chain reactions referred to as Fenton chemistry, offers a new way to target treatment-resistant
cancers (Doll et al., 2019). We conceive here that iron oxide-filled nanovaccines (IONVs) can exploit the
biochemical hallmarks of the TME for in situ ‘‘self-generation’’ of H2O2, which when converted by the
IONV into highly toxic ROS, via Fenton chemistry and acting as peroxidase catalyst, drives and concen-
trates complementary or synergistic antitumor mechanisms in the TME. We chemically programmed the
IONVs to provide (1) non-invasive imaging and effective delivery of combination therapy to the tumor
and tumor draining lymph nodes (TDLNs), (2) nanoparticle-tuned disassembly to reveal ‘‘stealth’’ immunos-
timulatory features, (3) an iron oxide core that can artificially reprogram in situ pro-tumoral M2 macro-
phages into antitumorM1macrophages (Li et al., 2019), and (4) improved tumor antigen cross-presentation
by a pH-responsive hydrazone tumor antigen linkage strategy (Scheme 1). Importantly, since interferon
gamma (IFN-g) released from immunotherapy-activated CD8+ T cells has recently been shown to trigger
ferroptosis-specific lipid peroxidation in tumor cells (Wang et al., 2019), we utilize the IONV iron content
Scheme 1. Design, Mechanism and Features of IONVs
Design and mechanism of action of inherently therapeutic IONVs with chemically programmedmulti-functional elements
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and peroxidase-like activity to sensitize tumor to ferroptosis, further stimulating the immunotherapy and
overcoming immunotherapy resistance mechanisms.
In aggressive and established melanomas, we performed a screening of different immune adjuvants in
nanoparticle-free vaccines and then sought to systematically assess and quantify how specific nanoparticle
engineering design elements impact the responses to therapies. Finally, the combination of IONV- and
antibody-mediated nuclear imaging and modulation of cell populations in the TME resulted in complete
eradication of established tumors in vivo, eliciting long-lived protective antitumor immunity in treatedmice
with no observed toxicities. This work provides proof-of-concept demonstration of how iron and IONP-
dependent catalytic activity can harness TME biochemical features to improve vaccination and immuno-
therapy activation of ferroptosis and potentially become one of the centerpieces for immunotherapy
enhancement with nanomedicine.
RESULTS
Prophylactic and Therapeutic Implications of Different Toll-like Receptor Agonists
Toll-like receptor agonists (TLRa) have demonstrated potential for the treatment of cancer through direct
and indirect activation of different leukocytes of the innate and adaptive immune systems (Schmidt, 2006).
To use intrinsically therapeutic catalytic nanovaccines, we first performed a screening of different Tara’s
against highly aggressive melanoma tumors, which are characteristically difficult to treat or ‘‘cure’’ once
large visible tumors have developed (B16-F10 cells expressing the xeno-antigen ovalbumin [OVA]). The
prophylactic implications and efficacy of the TLRa as a vaccine adjuvant was studied by subcutaneously
administering low doses (1–5 mg) with full-length OVA. The studies revealed the efficacy of targeting syn-
ergistic TLR signaling, achieved by combining imiquimod (R837, synthetic small molecule serving as TLR7-
specific ligand) and polyIC (synthetic double-stranded RNA serving as a TLR3 agonist) (Figures 1A–1C), as
well as the anti-melanoma protection achieved with unmethylated CG-enriched oligodeoxynucleotides
(CpG ODNs), a TLR9 ligand. In comparison, the TLR4 agonists Xcc-LOS (Xanthomonas campestris lipooli-
gosaccharides) (Traini et al., 2019) and LPS (lipopolysaccharide), and the detoxified ligand MPLA (mono-
phosphoryl lipid A), successfully used as adjuvant in clinically approved vaccines and tested in several clin-
ical trials for anti-cancer vaccines, were less effective at generating protective antitumor immunity (Cluff,
2009). In order to study the in vivo antitumor effects of these adjuvants, we subcutaneously implanted
the melanoma tumor and after the tumor had become established (ca. 7 days), we administered the
best-performing adjuvants (polyIC-R837 or CpG ODNs) and OVA. The potential of cisplatin chemotherapy
to convert the tumor into a permissive site for the activation of an adaptive immune response within the
tumor (Kang et al., 2013), even without administration of adjuvant, was also studied. Co-treatment with
chemotherapy and tumor antigen administration led to slower tumor growth and longer survival compared
with monotherapy (Figures 1D and 1E), indicating that priming of the tumor-specific immune response with
chemotherapy is possible with OVA antigen delivery into the TME. However, although the generation of
antitumor effects achieved by CpGODNs and polyIC-R837 was with complete absence of systemic toxicity,
the chemotherapy acting as vaccine adjuvant is accompanied by systemic toxicity and rapid weight loss
initiated following the first injection, an effect that exacerbated with each dose (Figure 1F).
Improvement of Vaccination Efficacy Derived from Nanocarrier Design
Delivery of tumor antigens and vaccine adjuvants to the tumor and TDLNs is important to prime antitumor
immunity and fight against tumor immune escape mechanisms. Hence, for safe and robust vaccination a
strategy is to engineer nanocarriers that enable vaccine effective delivery to the lymph node microenviron-
ment (Irvine et al., 2013; Storni et al., 2005). The adjuvant can help to convert the immunodormant (‘‘cold’’)
TME into an immunostimulatory (‘‘hot’’) one while taking advantage of tumor-associated antigen drainage.
Since various physicochemical properties can be tailored to enable effective drug delivery to lymph nodes,
nanocarrier design is critical (Schudel et al., 2019).
We created PEG-phospholipid (PEG-PL)-stabilized IONP-bound oleates carrying adjuvant/antigen
(IONVs), which led to micelles <100 nm with good stability for up to 2 weeks (Figures S2–S5).(Carion
et al., 2007; Cobaleda-siles et al., 2014) We included the cationic lipid DOTAP to self-assemble polyIC
and CpG upon mixing via electrostatic interactions between the positive charges of the lipid and the nega-
tive charges of the nucleic acid-based TLRas. The incorporation of R837 to IONVs was conducted by its
intercalation into the polyIC dsRNA chain, forming polyIC-R837 complexes as shown in our previous
work (Bocanegra Gondan et al., 2018). The model antigen OVA was successfully adsorbed by iron oxide
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nanoparticle-filled micelles (mIONPs) containing DSPE-cPEG(2000)-PL with COOH end groups exploiting
the concept of ‘‘nanoparticle-protein corona’’(Nguyen and Lee, 2017). To investigate the delivery of the
IONVs to lymphatic tissues and tumor, we 67Ga-radiolabeled the IONP surface exploiting the similarity be-
tween Ga(III) and Fe(III) as reported previously (Ruiz-De-Angulo et al., 2016). This smart organic synthesis-
free process, which involves reaction of the readily obtained radiocation [67Ga][Ga(H2O)6]Cl3 (aq.) with the
anionic IONVs at 70C for 30 min followed by purification by ultracentrifugation, proceeded with very good
yield (>80%; Figures 2A, 2B, and 2C). The 67Ga-doped IONVs showed excellent stability, with less than 10%
of the bound 67Ga being released over 24 h even when challenged with 106-fold molar excess of DOTA
chelator, and therefore suitability for in vivo tracking (Figure 2C).
SPECT/CT imaging results showed that these IONVs selectively accumulate in LNs and tumor up to 24 h
(Figures 2D–2F and S6 and S7). Particles cleared from the injection site were excreted into the urine and
accumulated at proximal and distal draining LNs within 3 h post injection (Figures 2D and S6), which is
consistent with self-lymphatic delivery and confirms the lymphatic drainage from the tumor implantation
site to tumor-draining lymph nodes (TDLNs). Therefore, the in vivo biodistribution experiments demon-
strated IONVs are sufficiently small and stealthy to be rapidly taken up into lymphatic vessels and transit
to the draining LN after subcutaneous (SC) injection.
To investigate the therapeutic efficacy of nanoparticle vaccination, mice were treated with non-covalently
formed IONVs with the polyIC-R837 or CpG ODNs (Figure S8) adjuvant and OVA. The IONVs achieved
Figure 1. In Vivo Evaluation of the Effect of Vaccination with Different TLR Agonists and Cisplatin Chemotherapy
as Adjuvants
(A–C) In the prophylactic approach, C57BL/6 mice (n = 5) were immunized subcutaneously on days 0 and 14 with 5 mg of
OVA free or in combination with TLR4 agonists Xcc-LOS, MPLA, LPS (1 mg/mouse), TLR3 agonist pIC (4 mg/mouse), TLR7
agonist R837 (2 mg/mouse), pIC-R837 or TLR6 agonist CpG ODNs (5 mg/mouse). Mice were challenged with 3 3 105 B16-
F10(OVA) cells in the right back on day 21 after first immunization. (A) Average tumor growth curves and (B) Kaplan-Meier
survival curves. (C) Comparison of tumor volume of different experimental groups at day 17 after tumor challenge. The
data show mean G SEM from a representative experiment.
(D–F) To exploit for cancer therapy C57BL/6 mice (n = 5) were treated on days 7, 10, and 13 after B16-F10(OVA) cells
injection in the right back. Animals were subcutaneously administered with 10 mg of OVA free or in combination with pIC-
R837 (4 and 2 mg, respectively), CpG ODNs (10 mg), and cisplatin (intraperitoneal, 100 mg). In this last group, cisplatin was
administered with 60 mg of OVA antigen subcutaneously, in order to mimic the literature. (D) Average tumor growth
curves, (E) Kaplan-Meier survival curves, and (F) animal body weight change over the experiment. Arrows indicate the days
of therapy administration. Data are shown as mean G SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-
tailed unpaired Student’s t test (A, D, and F), by log rank (Mantel-Cox) test against OVA (SC) group (B and E), and one-way
ANOVA followed by Tukey’s test (C). See also Figure S1.
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significantly slower tumor growth relative to the treatment with free polyIC-R837 and OVA or to the clinical
‘‘gold standard’’ alum orMontanide ISA adjuvants. Only the treatment with the IONVs achieved 100% sur-
vival through the study endpoint at 30 days after tumor implantation, and the therapeutic effect was elicited
with complete absence of systemic toxicity (Figure S8). Notably, the SC administration into the hock of
mIONP-OVA without the TLRa adjuvant and even of mIONP alone showed an antitumor effect that is
the same or superior to antigen administered intratumorally (IT), highlighting an important intrinsic
IONP therapeutic contribution (Figure 3A).
In line with these findings and to investigate whether IONVs promote a long-term immune response involving
tumor antigen-specific CTL activation, we conducted prophylactic vaccination experiments. On day 70 after the
last immunization, animals were rechallengedwithmelanoma cells in the contralateral side. Six weeks later,mice
were sacrificed and blood and spleens were collected for immune analysis (Figure S9). IONVs were found to
enable an enhanced overall specific immune response, resulting in higher percentages of OVA-specific CTLs
that exhibited a multifunctional killing phenotype, as demonstrated by the increased frequency of IFN-g and
TNF-a-producing T cells and increased expression of the degranulation molecule CD107a. Moreover, higher
levels of antigen-specific Th1-type CD4+ Th cells (producing IFN-g andTNF-a Th1-type cytokines) and increased
Figure 2. Radiolabeling and SPECT/CT Tracking of IONVs Allow Non-invasive Monitoring of Therapy Outcome
(A and B) The radiocation [67Ga][Ga(H2O)6]Cl3(aq.) is loaded by heating with the anionic IONVs and following purification
by ultrafiltration using a 100k membrane results in 67Ga-doped IONVs inradiolabeling yields > 80%. (C) The chelator
DOTA (present in 106 molar excess relative to IONP) is able to remove <10% of the IONP-bound 67Ga over a 24-h period.
(D–F) Biodistribution study of 67Ga labeled mIONP-CpG ODNs (23.6 mg of magnetite, 43.4 MBq) injected in the hock of
melanoma tumor-bearing mice. (D) SPECT/CT images 3, 24, and 48 h post injection (coronal and sagittal views). Ex vivo
analysis by (E) SPECT/CT and (F) gamma counter 48 h after injection. T, tumor; bLN, brachial LN; aLN, axillary LN; Lu,
lungs; L, liver; S, spleen; K, kidneys; iLN, iliac LN; sLN, sciatic LN; inLN, inguinal LN; pLN, popliteal LN; I, injection site. See
also Figures S6 and S7.
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quality of the T cell response based on the analysis of effector (TEM) and central memory (TCM) CD8
+ T cell per-
centages in spleen were also observed. The characterization of the immune responses confirmed the ability of
IONVs to elicit potent and durable antitumor immunity.
To elucidate potential intrinsic adjuvant properties, we assessed the status of DCs after incubation with the
designed mIONP alone and IONVs carrying TLRa adjuvants and OVA. The expression of the co-stimulatory
signal molecules CD80 and CD86 as well as the major histocompatibility complex (MHC) class II, which are
involved in the initiation of T cell-mediated immune responses against tumors, was observed with the
mIONP alone and was comparable with the expression induced by stimulation with free TLRa agonists
(Figure 4).
This result highlights the importance of the mIONPs toward promoting proper DC maturation for T cell
clonal expansion and differentiation to CD8+ cytotoxic lymphocytes (CTLs) and improved co-presentation
of antigen to CD4+ T helper (Th) cells. None of the mIONP formulations showed toxicity in DCs. Notably,
the induction of the expression of PD-L1, which inhibits T cell effector function (via engagement of the PD-1
receptor expressed on activated T cells), was observed on DCs activated by the TLRa agonists and mIONP
formulations (Figures 4 and 5). This result suggests that blocking PD-1/PD-L1 signaling could represent an
opportunity to augment the antitumor effects of these systems.
Hydrophobicity as ancient damage associated molecular pattern (DAMP) can be used to activate innate
immune responses (Seong and Matzinger, 2004). To investigate if the micellar structure with ‘‘stealth’’ hy-
drophobic portions around IONPs (hydrophobic oleic acid coating covered by PEG-PL layer) contributes
toward delaying tumor growth in vivo, mice with established tumors were treated with drug-free mIONPs
differing in the amphiphilic organic coating and IONP core. If the concept that nanoparticle-tuned disas-
sembly by amphiphilic polymer release from a mIONP system to reveal hydrophobic portions can be used
as an IONV design principle to trigger an improved activation of an innate immune response capable of
Figure 3. In Vivo Evaluation of the Therapeutic Effect Derived from the ‘‘Stealth’’ Hydrophobic IONP Coating and
IONP Size
C57BL/6 mice (n = 5) were treated on days 7, 10, and 13 after B16-F10(OVA) cells injection in the right back. (A) intrinsic
adjuvant activity of mIONP was analyzed by treating animals with 10 mg of OVA antigen alone (IT) or in combination (as
protein corona adsorbed by the nanoparticle) with mIONP (SC injection into the hock [ankle]; 61 mg magnetite); (B)
nanoparticle size and exposure of coating was studied by injecting animals with different IONP-filled micelle designs
(101 mg magnetite) peritumorally (SC, 2 cm from tumor); and (C) the effect of IONP coating nature was examined by
comparing the co-administration (SC, right back) of B16-F10(OVA) cancer cells with IONPs with polar (ferumoxytol) or
apolar (mIONP) coating (12 mg Fe/kg, 332 mg magnetite).
(A–C) Results are shown as average tumor growth curves (upper graphs) and Kaplan-Meier survival curves for each case
group (lower graphs). Arrows indicate the days of therapy administration. Data are shown as mean G SEM. *p < 0.05,
**p < 0.01 by two-tailed unpaired Student’s t test (A–C upper graphs) and by log rank (Mantel-Cox) test against PBS/NaCl
(0.9%) control group (A–C lower graphs).See also Figures S8–S10 for further in vivo studies and Figure S2 for
characterization of the hydrophobic IONPs.
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influencing tumor immunity and growth is correct, thenmodulating the stability of the intercalation with the
IONP-bound oleates would be expected to affect the extent of tumor growth inhibition. Indeed, the results
showed greater inhibition of tumor growth and prolonged survival with administration of mIONP coated
with DPPE-mPEG(2000)-PL with methoxy end groups compared with PMAO-PEG as amphiphilic polymer
coating (mIONP-trapped) (Figure 3B). This is consistent with the reported high stability of the PMAO-
PEG coating (Yu et al., 2006). Using DPPE-mPEG(2000)-IONP micelles containing IONP core sizes of
20 nm (mIONP-big) instead of 6 nm the intrinsic therapy effects were abrogated, which could be derived
from an inefficient migration toward TDLNs (Figures 3B and S10).
Administration of the US Food and Drug Administration (FDA)-approved iron supplement ferumoxytol has
been found to promote tumor growth regression (Zanganeh et al., 2016). However, when the B16-F10(OVA)
melanoma cells were implanted with or without ferumoxytol and compared with an equivalent dose of
mIONPs, only the mIONP was able to suppress tumor growth highlighting the superior design features
of the mIONPs (Figure 3C).
Antigen Attachment Mode Alters the Efficacy of IONVs
The concept of antigen-specific cancer immunotherapy is based on the generation of antigen-specific CTLs
that recognize and destroy tumor cells that present antigen-derived peptides using cell surfaceMHC class I
molecules (Embgenbroich and Burgdorf, 2018). However, many current strategies lead to the ineffective
generation of antigen-specific CTLs after vaccination. Our approach to overcome this challenge is based
on creating chemically engineered antigen-packed NPs, which can deliver antigen to DCs in the tumor and
TDLNs and utilize pathogen-like endocytosis mechanisms. A suitably designed NP can promote the
release of antigen in response to intracellular environmental stimuli (e.g., acidic pH) to promote cross-pre-
sentation (i.e., presentation of the internalized tumor antigen by means of the MHC-I pathway). Impor-
tantly, it has been postulated that lipid peroxidation in DCs can also cause endosomal antigen release
for cross-presentation(Dingjan et al., 2016). Our converged solution is to exploit the peroxidative activity
of the nanoparticle (vide infra) while optimizing NP-enhanced antigen delivery by means of a more efficient
antigen chemical attachment mode. We developed a bis-aryl hydrazine linkage strategy for the coupling of
Figure 4. Comparison of DC Activation Elicited by mIONPs and Potent Immunostimulatory TLRa
Primary culture of BMDCs was incubated overnight with increasing concentrations of mIONPs (magnetite mg/mL) and
standard amounts of TLR agonists (mg/mL) diluted in media.
(A) Activation and immunosuppressive marker expression measured by flow cytometry and expressed as relative mean
fluorescent intensity (MFI).
(B and C) (B) Cytokine production on cell culture supernatant measured by ELISA and (C) cytotoxic effect of the different
stimulus after overnight incubation (MTT assay). Results are shown as mean G SEM of three independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA (A and C) and by two-way ANOVA (B) followed by
Tukey’s test. See also Figure S3 for characterization of mIONPs
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mIONPs to the tumor antigen, which provides rapid, monitorable, and high yields of conjugation and sta-
bility at physiological pH, while enabling antigen release at endosomal pH for efficient cross-presentation
(Traini et al., 2019).
To investigate the importance of the new antigen attachment mode, we treated mice with IONVs based on
OVA adsorbed to the IONP micelles as a corona (mIONP-OVA(ads)) and its covalent conjugation by hydra-
zone linkages (mIONP-OVA(hyd)) (Figure 6). Although vaccination with adjuvant mIONP-polyIC-R837 co-
administered with mIONP-OVA(ads) or mIONP-OVA(hyd) significantly suppressed tumor growth and the
tumors were on average similar in size, only mice in the mIONP-OVA(hyd)-treated group survived tu-
mor-free over a long period of monitoring (CR 40%) (Figure 6C). This result reveals that hydrazone bio-
conjugation chemistry optimizes therapeutic immune responses to the IONVs.
The Iron Oxide Core Elicits Antitumor Immunotherapy Efficacy
Having established several features that improve the IONV vaccination efficacy, we considered whether
other biocompatible nanoparticles previously used for development of nanovaccines such as gold nano-
particles (AuNPs) (Almeida et al., 2014) might elicit similar antitumor efficacy. Studies have highlighted
the potential of polyethylenimine (PEI) (Shen et al., 2017; Liang et al., 2018), one of the well-studied cationic
polymers used as a transfection reagent for decades, for vaccine development. The mechanisms for the
intrinsic immunoactivation function of PEI are diverse and include the triggering of ‘‘danger signals’’ in an-
tigen-presenting cells and the ability to elicit ROS (Shen et al., 2017). We prepared AuNPs coated with PEI
(Garaikoetxea Arguinzoniz et al., 2015) and by exploiting its positive charge, we developed PEI-modified
AuNPs suitable for forming complexes with the anionic polyIC-R837 adjuvant. Moreover, the AuNP-
s@PEI-polyIC-R837 complexes had an optimal size for effective lymphatic delivery (Figure S11). Strikingly,
the antitumor efficacy of this system was similar to that of mIONP-OVA(hyd) alone. Hence, the AuNP@PEI-
polyIC-R837 complex is not able to replicate the adjuvant effects of mIONP-polyIC-R837 (Figure 6) owing to
the intrinsic effects arising from the IONP core (see below).
Catalytic Properties and Cell Responses to mIONPs/IONVs: Creating the ‘‘Perfect Storm’’
and Catalytic Therapy
IONPs have been shown to perform peroxidase-like functions, which have led to proof-of-concept demon-
strations of tumor-responsive catalytic nanomedicine (Huo et al., 2017; Lin et al., 2018). We reasoned that
Figure 5. Comparison of DC Activation with mIONP-OVA (Magnetite-Antigen, mg/mL) and OVA
(A–C) (A) Expression of surface markers measured by flow cytometry, (B) cytotoxic effect (MTT assay), and (C) cytokine
production measured by ELISA. Results are shown as mean G SEM of three independent experiments. *p < 0.05, **p <
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the unique antitumor effectiveness of the IONVs may be underpinned by its catalytic activity on iron and
ROS-mediated processes in macrophages and cancer cells.
The peroxidase-like activity of mIONP was assayed by the colorimetric reaction of H2O2 with the peroxi-
dase substrate 3,30,5,50-tetramethylbenzidine (TMB), which upon oxidation turns blue (ε652 = 3.9 3 10
4
M1 cm1, Figure 7A). mIONP catalyzed the peroxidative reactions at the acidic conditions found in the
TME and endosomal compartments to which the nanovaccines are targeted, whereas this activity was min-
imal at physiological pH. This activity was further confirmed by oxidation of o-phenylenediamine (OPD)
(Figure 7B). UV-vis absorption time course curves indicated that the mIONPs had a higher catalytic activity
than ferumoxytol and AuNPs under the same conditions (Figure 7A). The catalytic contribution of iron ions
leached from mIONPs was found to be negligible (Figure 7A), confirming that the peroxidative activity is
carried out by the nanoparticles.
Varying the concentration of H2O2 and TMB,Michaelis-Menten steady-state kinetics were applied to deter-
mine the catalytic performance of the IONP micelles in terms of catalytic rate (kcat), maximal rate (Vmax), Mi-
chaelis constant (KM), and catalytic efficiency (kcat/KM) (Figures 7C and 7D). The kinetic parameters (KM =
0.338 mM, Vmax = 6.59 3 10
8 M1 s1) are indicative of strong catalytic performance (e.g., better than
horseradish peroxidase [HRP] in terms of H2O2 affinity, for which the KM is 3.7 mM). It is known that, during
tumor growth, the TME generates a substantial amount of H2O2 (50–100 mM) (Szatrowski and Nathan,
1991), and it is reasonable to expect that this H2O2 production will be significantly enhanced by the
Figure 6. In Vivo Evaluation of the Therapeutic Efficacy Arising from an Optimized Antigen Nanoparticle
Attachment and Adjuvant Core Material
C57BL/6 mice (n = 5) were treated on days 7, 10, and 13 after 3 3 105 B16-F10(OVA) cells injection in the right back with
vehicle, 10 mg of OVA adsorbed by IONP (mIONP-OVA(ads)), conjugated to IONP by hydrazone linkages (mIONP-
OVA(hyd)) alone or co-administered with adjuvants (mIONP-pIC-R837 or AuNP@PEI-pIC-R837 (4 mg of pIC and 2 mg of
R837, 30 mg magnetite, and 5 mg of gold)).
(A–C) (A) Average tumor growth, (B) Kaplan-Meier survival plot, and (C) individual tumor growth curves. CR, complete
rejection. Arrows indicate the days of therapy administration. Data are shown as mean G SEM. *p < 0.05, **p < 0.01,
***p < 0.001 by unpaired Student’s t test between indicated groups (A) and by log rank (Mantel-Cox) test against
AuNP@PEI-pIC-R837 group (B). See also Figures S3–S5 for IONV characterization, Figure S11 for AuNP@PEI
characterization, and Figure S12 for further statistical analysis.
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immunostimulatory TLRa-loaded IONVs. The data show that mIONPs catalyze the oxidation of TMB at iron
concentration of 150 mM, which is below the concentration used in the in vivo and in vitro studies.
Tumor-associated macrophages (TAMs) often represent a dominant proportion of the immune cell infil-
trate that can promote tumor progression, and suppress antitumor immune responses, but can be poten-
tially harnessed to treat cancer (Bronte and Murray, 2015; Gabrilovich et al., 2012). Having demonstrated
high catalytic peroxidative activity, we investigated the effects of mIONP on macrophages and cancer cells
in direct cell-to-cell contact co-cultures. For comparison, the cells were also treated with cisplatin, polyIC,
and R837. Although the widely used chemotherapy drug is not effective at killing the melanoma cells, it
leads to complete macrophage obliteration (Figures 8A and 8B). PolyIC and R837 induced melanoma
cell death but only when combined, synergizing to significantly enhance cytotoxicity in the melanoma cells
with no toxic effects in macrophages. Free mIONPs were as effective at killing the melanoma cells as the
combination of polyIC and R837. Notably, administration of mIONP-polyIC-R837 killed >90% of the target
melanoma cells with >70% macrophage viability.
We then performed the studies with both types of cells in mono-cultures and in co-cultures separated by
a porous membrane allowing free diffusion treatment and biochemical cell communication while restrict-
ing cell migration (Figure S13A). Again, mIONP induced more toxicity in melanoma cells than in macro-
phages and displayed an overall anticancer effect comparable with the highest dose of cisplatin (100 mM)
(Figures 8A, 8B, S13B, and S13C). However, the results clearly highlighted the relevance of cell-to-cell
contact interactions between the immune and melanoma cells to potentiate the mIONP immunothera-
peutic effect.
We measured the production of IL-10, an effector molecule of M2 macrophages, which as an anti-inflam-
matory cytokine plays a critical role in limiting the host pro-inflammatory immune response and promoting
tumor immune escape. Cultures treated with TLR ligands (including the TLR4 ligand LPS) or cisplatin ex-
hibited high levels of IL-10, whereas treatment with IONP-filledmicelles andmIONP-pIC-R837 led to essen-
tially the same level of immunosuppressive IL-10 as the non-treatment control (Figure S13E). Thus, the
mIONP-pIC-R837 provides effective melanoma cell killing overcoming mechanisms that impair antitumor
immunity.
Figure 7. Comparison of Catalytic Properties of mIONPs AuNPs and Ferumoxytol
(A and B) (A) Peroxidase-like activity of mIONPs at different pH values, AuNP@PEI, ferumoxytol, and released free iron
cations in catalyzing the oxidation of 3,30,5,50-tetramethylbenzidine (TMB). (B) Catalytic oxidation of o-phenylenediamine
(OPD). Concentrations of [Fe] = 150 mM for mIONPs and 550 mM for ferumoxytol were used.
(C and D) Michaelis-Menten kinetics plots for the oxidation of TMB in the presence of H2O2 at varying concentrations of
(C) H2O2 and (D) TMB, based on data (mean G SEM) from three independent experiments.
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Figure 8. Cell Death Triggered by mIONPs and IONVs in Cell-to-Cell Contact Co-cultures of Melanoma Cells and
Macrophages and Induction of Ferroptosis
(A and B) Cell viability was measured by flow cytometry following 24-h treatment (A) B16-F10(OVA) melanoma cells and (B)
RAW 264.7 macrophages in cell-to-cell contact co-culture approach (77 mg/mL magnetite = 1 mM of Fe). Data are shown
as mean G SEM (n = 3).
(C) Effects of Erastin on the cell viability of RAW 264.7 (green bars) and B16-F10(OVA) (blue bars) in their respective mono-
cultures, after 24 h of exposure determined by MTT assay. Data were normalized to the absence of treatment.
(D) Effects of mIONPs (0.5 mM of Fe) on the cell viability of B16-F10(OVA) after 24 h of exposure upon 24-h
preconditioning with increasing concentrations of Erastin. Data were normalized to the absence of mIONP treatment for
each Erastin concentration (solid green bars). Data are shown as mean G SEM (n = 4).
(E) Reaction of Liperfluo with hydroperoxide lipids to generate fluorescence Liperfluo-Ox.
(F) B16-F10(OVA) incubated with IONPs (1 mM of Fe) for 24 h. Representative flow cytometric profiles are shown to
demonstrate lipid peroxides with Liperfluo signals, where cells treated with cumene hydroperoxide are used as positive
control. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA followed by Tukey’s test (A, B) and by two-
way ANOVA followed by Sidak’s test (C, D). See also Figure S13.
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Finally, we sought to identify whether cancer cell death was due to ferroptosis. Using erastin as a ferroptosis
activating agent, the results showed that themelanoma cells aremuchmore susceptible to ferroptosis than
macrophages (Figure 8C). This result is consistent with other studies showing that cells of the innate im-
mune system display resistance to ferroptosis (Matsushita et al., 2015). Moreover, a recent study has shown
that, antitumor M1 macrophages display resistance to ferroptosis, whereas M2 macrophages are sensitive
to pro-ferroptosis stimulation and that this is linked to inducible nitric oxide synthase (iNOS)/NOd enrich-
ment (Kapralov et al., 2020).
Importantly, mIONP by providing a source of iron, ROS, and catalytic activity can be used to trigger cancer
cell ferroptosis (Figure 8D). Since one of the characteristics of ferroptosis is the accumulation of lipid hydro-
peroxides, measuring lipid peroxidation is important for evaluating whether ferroptosis occurs. To directly
reveal whether lipid hydroperoxides are formed following incubation of the melanoma cells with mIONPs,
we used Liperfluo, which reacting with hydroperoxides yields the fluorescent Liperfluo-Ox product (Fig-
ure 8E).(Yamanaka et al., 2012) The flow cytometry studies demonstrated the presence of hydroperoxide
lipids in melanoma cells treated with mIONP even without erastin (Figure 8F).
Combination Immunotherapy with Checkpoint Inhibitors: ‘‘Pushing the Gas’’ and ‘‘Releasing
the Brakes’’
Immunotherapy with ICIs has created a paradigm shift in clinical oncology. The focus has been blocking
inhibitory signals to release the brake on the activity of T cells present in the TME. Recently, several studies
reported that this type of immunotherapy leads to production of IFN-g, which plays a pivotal role in host
antitumor immunity (Peng et al., 2012; Chen et al., 2009). However, IFN-g is a potent inducer of PD-L1
expression and tumors exploit this as a strategy to escape antitumor immunity (Mandai et al., 2016). Impor-
tantly, a recent study demonstrates that immunotherapy-activated CD8+ T cells promote tumor cell lipid
peroxidation and sensitize tumors to ferroptosis through IFN-g (Wang et al., 2019). Hence, targeting
and enhancing ferroptosis in tumors may be a promising new route to improve the efficacy of cancer immu-
notherapy (Wang et al., 2019) with additive or potentially synergistic interaction between immunotherapy
and induction of ferroptosis. Immunotherapy studies are progressively being directed to immunostimula-
tory antibodies that instead of releasing the brakes on the immune system to boost antitumor immunity can
promote activation pathways (i.e., ‘‘step on the gas’’) (Mahoney et al., 2015). In this context, agonistic anti-
OX40 antibodies are being tested in several phase I/II clinical trials either as monotherapy or in combina-
tion with other immune-modulating agents. They possess the dual function of enhancing the activation of
the tumor infiltrating effector T cells (Teff) and inhibiting the immunosuppressive Treg cells (Aspeslagh et al.,
2016). Recent studies have shown that, although systemic delivery of anti-OX40 may favor activation of pe-
ripheral lymphocytes to promote systemic toxicity, intratumoral administration is better for targeting tu-
mor-infiltrating lymphocytes and to promote novel mechanisms of action such as depletion of intratumoral
Treg and abscopal effects (i.e., a local low-dose immunotherapy eliciting a systemic antitumor immune
response avoiding systemic toxic events) (Marabelle et al., 2013; Hebb et al., 2016).
On the basis of these studies and the results shown in this work, we explored combination of the IONVs with
an antagonistic anti-PD-L1 (CPD-L1) and agonistic anti-OX40 antibodies (COX40).
We first radiolabeled the immunostimulatory mAbs (monoclonal antibodies) with 89Zr by antibody modifi-
cation with the bifunctional chelator p-isothiocyanatobenthyl-desferrioxamine and addition of [89Zr]Zr-ox-
alic acid solution (Vosjan et al., 2010). We then confirmed the expression of OX40 and PD-L1 in the TME by
89Zr-immuno-PET imaging and observed high uptake of both radiolabeled antibodies in the tumor and in
the spleen (Figures 9A and 9B). The analysis of tumor-infiltrated immune cells by flow cytometry showed
high levels of OX40+ T cells in the tumor and TDLNs. Notably, CD4+OX40+ T cells showed double-positive
expression of T cell activation markers CD44 and CD25 (Figures 9C–9E), suggesting an optimal environ-
ment for the immunostimulatory mAbs-based therapies.
To study the eradication of established tumors by the combination immunotherapy, mice were treated with
IONVs, and, on days 1 and 4 after each vaccination, with CPD-L1 administered (100 mg) intraperitoneally.
Although IONVs alone induced delayed growth of the tumor, all animals eventually developed tumor.
However, with the combination of vaccination and CPD-L1 treatment in addition to animals showing partial
response to the therapy, 40% of mice were free of tumor 90 days after the inoculation of themelanoma cells
(Figures 10A–10C). To evaluate whether combination with COX40 monoclonal antibodies provides
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additional therapeutic benefit, mice were co-treated with an ultra-low dose of COX40 antibody (10 mg) deliv-
ered intratumorally and the IONVs administered subcutaneously at a tumor distant site. Again, the results
consistently show 100% tumor eradication in mice and significantly reduced tumor progression with the
combination treatment compared with the monotherapies or checkpoint-inhibition combination therapy
with COX40 and CPD-L1 antibodies (Figures 10A–10C). Moreover, when animals were re-challenged with
the melanoma cells (90 days after first tumor challenge) they remained tumor-free for 30 days, compared
with none for controls (Figures 10D and 10E).
DISCUSSION
Herein, we report the rationale for a systematic nanoparticle engineering design that exploits the iron con-
tent, nanoenzymatic activity, biochemical properties in TME, and chemical and structural features of IONVs
as a generalizable therapeutic platform for cancer immunotherapy. A major finding was that iron and
peroxidase-like activity of IONVs can be used to exploit and convert conditions in TME (often leading to
therapy resistance) into a site that overcomes immunosuppressive mechanisms and elicits potent and du-
rable antitumor responses that eradicate established tumors. The findings show how IONVs can unite and
optimize concurrently effective vaccine delivery for inducing anticancer immunity, immune checkpoint
blockade, and cancer cell ferroptotic-cell death to augment the therapeutic index of combination therapy
and immunotherapy approaches.
Nanoparticles have been extensively studied to improve the delivery of chemotherapy drugs, but the effi-
cacy of this approach has been plagued with disappointing results in clinical trials (Bourzac, 2016; Hare
et al., 2017). In contrast, cancer immunotherapy using nanoparticle-based vaccines is a promising new
area in which FDA-approved polymers and nanocarriers such as poly(lactic-coglycolic acid) (PLGA), lipo-
somes, and phospholipid nanodiscs have already allowed various degrees of success (Maldonado et al.,
2015; Rosalia et al., 2015; Varypataki et al., 2016; Kuai et al., 2017; Min et al., 2017; Xiaoding et al., 2017;
Ling et al., 2019). It is becoming clear that nanomedicine can provide innovative solutions for immuno-
therapy (Irvine and Dane, 2020). Inorganic nanomaterials offer additional features for modulation of im-
mune responses and non-invasive vaccine tracking owing to intrinsic adjuvant and imaging properties
(Lee et al., 2012; Cobaleda-siles et al., 2014; Ruiz-De-Angulo et al., 2016; Wang et al., 2016; Bocanegra Gon-
dan et al., 2018). In this study we show that engineered iron oxide nanoparticles (IONPs) can become a
cornerstone for enhancing immunotherapy owing to the coupling of catalytic activity with immunomodu-
lation. They are suitable for medical oncology use owing to excellent safety profiles, biodegradability and
Figure 9. In VivoDetection of the Expression of PD-L1 and OX40 Immune Receptors by Immuno-PET Imaging and
Subsequent Analysis of Infiltrating Immune Cells Allowed Characterization of TME Status
(A) PET images were acquired 24, 48, and 72 h after administration of the radiolabeled anti-PD-L1 and anti-OX40
antibodies (80–100 mg, 1–7 MBq).
(B–E) (B) Antibody accumulation in tumor and spleen expressed as injected dose percentage per cm3 (% ID/cm3). Analysis
of immune cells phenotype found in the spleen, TME and TDLN: (C) CD4+ and CD8+ T cell percentages, (D) OX40+
T cell0020percentages, and (E) activation profile of CD4+OX40+ T cells. Data are shown as mean G SEM (n = 7).
ll
OPEN ACCESS
iScience 23, 101499, September 25, 2020 13
iScience
Article
metabolization, facile synthesis and tuneability targeting enhancement of intrinsic therapy, and imaging
properties (Revia and Zhang, 2016). An important target is to surpass the recently discovered antitumor ac-
tivities of the FDA-approved IONP-based iron supplement ferumoxytol, which arise from activating and re-
polarizing macrophages via Fenton chemistry but requires administration of high doses (Zanganeh et al.,
2016). Moreover, ferumoxytol administration has been shown to exert anti-leukemic effects exploiting the
vulnerability of these cells to iron-based oxidative stress (Trujillo-Alonso et al., 2019). We show how adopt-
ing a systematic molecular engineering approach micelles filled with iron oxide nanoparticles can be en-
gineered to significantly surpass the antitumor effects of ferumoxytol.
Consistent with recent studies showing that nanoparticles can induce ferroptosis in cancer cells and
perform catalytic nanomedicine (Huo et al., 2017; Kim et al., 2016; Lin et al., 2018; Liu et al., 2018), the
mIONP’s iron-enabled and high peroxidase-like activity triggered selective cancer cell killing, but in partic-
ular in contact co-cultures with macrophages that alone could not induce cancer cell killing.
By targeting ferroptosis (Yang and Stockwell, 2016), which is induced by oxidative stress and characterized
by iron-dependent accumulation of lipid hydroperoxides and can be enhanced by the action of immune
Figure 10. In Vivo Evaluation of the Enhanced Effect of Combination Immunotherapy with IONVs and
Immunostimulatory mAbs
C57BL/6 mice (n = 5) were inoculated with 3 3 105 B16-F10(OVA) cells and treated with nanovaccines (10 mg of OVA, 4 mg
of pIC, and 2 mg of R837; 42 mg of magnetite) on days 4, 11, and 18. ICIs (100 mg of anti-PD-L1 (IP) and 10 mg of anti-OX40
(IT)) were administered on days 1 and 4 after each immunization.
(A–E) (A) Average tumor growth, (B) Kaplan-Meier survival plot, and (C) individual tumor growth curves. (D) Average tumor
growth and (E) Kaplan-Meier survival plot following re-challenge of melanoma cells in the contralateral back of cured
mice. CR, complete rejection. Arrows indicate the days of nanovaccines (black) and checkpoint inhibitors (blue)
administration. Data are shown as mean G SEM. *p < 0.05, **p < 0.01 by unpaired Student’s t test between indicated
groups (A) and by log rank (Mantel-Cox) test against mIONP-OVA(hyd) + mIONP-pIC-R837 group (B).
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checkpoint blockade-reinvigorated T cells (Wang et al., 2019), the IONVs combined with immunostimula-
tory mAbs can realize complete eradication of aggressive and establishedmelanoma tumors inmice.When
benchmarked against other treatments the melanomas proved to be essentially unresponsive to ferumox-
ytol treatment, adjuvant chemotherapy, vaccination with AuNPs, clinically approved aluminum hydroxide
and Montanide-based adjuvants, and a combination of mAbs targeting co-stimulatory and coinhibitory
signal in T cells (anti-OX40 and anti-PD-L1).
To target the sites of interest the inherently therapeutic IONVs incorporated a comprehensive and so-
phisticated delivery mechanism, which involves efficient delivery to TME and lymph nodes, efficient intra-
cellular delivery to DCs by pathogen-mimicking endocytosis, and a chemically engineered conditional
intracellular release and antitumor activity that exploits hydrazone bond cleavage and peroxidase-like
catalysis in acidic endolysosomes. The radiolabeling of IONVs and ICIs confirmed the mechanistic basis
for the combination therapy efficacy by enabling non-invasive monitoring of effective multi-pronged
therapy delivery and real-time assessment of expression of blocking and activating immune checkpoint
receptors.
Itemizing and evaluating the nanoparticle engineering features hypothesized to contribute to the enhance-
ment of therapeutic outcomes allows a rational and on-demand design of IONVs. As expected, improve-
ments were driven by several characteristics of the designed IONVs: (1) ability to locally deliver the multi-
pronged therapeutic cargo to tumor and TDLNs enabled by IONVs size characteristics (<100 nm and
spherical IONPs of 6 nm); (2) optimal tumor antigen delivery and cross-presentation through pH-responsive
hydrazone conjugation and peroxidase-like activity; (3) nanoparticle-tuned disassembly to activate the
‘‘stealth’’ immunostimulation by the pathogen-mimicking hydrophobic nature of the nanoparticle core,
which confers an intrinsic adjuvant activity to the nanosystem; and (4) iron and high catalytic activity of
the iron oxide core that allows effective and stable radiolabeling with 67/68Ga for therapy tracking, reprog-
ramming of macrophages, in situ generation of ROS, and further tumor cell sensitization to ferroptosis in
the TME.
Although several externally triggered bioengineering approaches such as PTT, PDT, MHT, and magnetic
navigation have demonstrated considerable promise for improving treatment outcomes with ICIs (Lucky
et al., 2015; Ni et al., 2018; Chao et al., 2019; Eranki et al., 2019), most face challenges for clinical imple-
mentation owing to the intrinsic limitations of these techniques. In contrast, use and administration of iron
and catalytically enhanced IONVs is easy to implement alongside chemotherapy, radiotherapy, and com-
plementary immunotherapies. The effectiveness of tumor antigen hydrazone bond conjugation is demon-
strated with full-length xeno-antigen OVA, yet this chemistry is readily applicable with peptide antigens
and neoantigens that could be generated in controlled synthesis or on site (Min et al., 2017; Kuai et al.,
2017). This offers a feasibility strategy to eventually achieve personalized treatments, which promises to
be the next big immunotherapy and cancer treatment breakthrough.
In conclusion, the results presented here show how chemically programmed IONVs can be used as a plat-
form for the engineering of vaccines that are intrinsically therapeutic exploiting TME reprogramming, and
the tumor susceptibility to iron- and ROS-dependent processes and redox stress that could be clinically
applicable during combination immunotherapy. Chemistry- and iron-enabled catalytic vaccines offer
intriguing opportunities to also invigorate immunotherapy combinations with chemotherapy and radio-
therapy and with other approaches such as PDT, PTT, MHT, and HIFU and magnetic navigation.
Limitations of the Study
Although the murine B16 melanoma model is widely used for preclinical assessment of immunotherapies,
the therapeutic efficacy of the chemically programmed IONVs in clinically relevant models of human cancer
needs to be undertaken. The intracellular mechanism(s) of antigen processing and presentation underpin-
ning cross-presentation is not investigated. The potential role of lipid peroxidation induced by the IONVs
also causing endosomal antigen release for cross-presentation is plausible but has not been investigated.
Other immune cell populations around TME after the treatment can be investigated to provide a more
comprehensive understanding of the IONV effects. How the mIONVs enhance ferroptosis and can be opti-
mized for this purpose and the demonstration of the synergistic induction of ferroptosis by the checkpoint
inhibitors will require additional studies.
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All commercially available reagents were used without further purification.  
Synthesis of hydrophobic IONPs: Hexane (99%; LABSCAN), chloroform (water 0.005%; 
LABSCAN), diphenyl ether (99%; Sigma Aldrich), dibenzyl ether (>98%; Alfa Aesar), 1,2-
hexadecanediol (>98%; Tokyo Chemical Industry Co. Ltd), oleic acid (90%; Alfa Aesar), 
oleylamine (70%; Sigma Aldrich), iron(III) acetylacetonate (99%; Strem Chemicals). IONP-
filled micelles synthesis (mIONPs): 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (ammonium salt) (DPPE-mPEG(2000)), 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (ammonium salt) 
(DSPE-cPEG(2000)), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (ammonium salt) (DSPE-aPEG(2000)), 1,2-dipalmitoyl-
3-trimethylammonium-propane (chloride salt) (DOTAP) lipids were purchased from Avanti 
Polar Lipids, Inc. Synthesis of IONVs: polyIC, CpG ODNs  and R837 TLRas were purchased 
from InvivoGen. Endotoxin-free ovalbumin was obtained from Hyglos GmbH. Succinimidyl 
6-hydrazinonicotinamide acetone hydrazone was purchased from Solulink and succinimidyl 
4-Formylbenzoate was purchased from Santa Cruz biotechnology. 2-Hydrazinopyridine-
2HCl was purchased from Fluorochem. PD MiniTrap G-10 desalting columns were obtained 
from GE Healthcare and Amicon ultra-0.5 mL centrifugal filters (100 KDa MWCO) and 
Amicon Ultra-4mL (10 KDa MWCO) were purchased from Merck. Radiolabeling studies: 
67Ga citrate solution was purchased from CuriumTM (Spain) and 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) from Macrocyclics (Inc. Dallas, 
USA). In vitro and in vivo experiments: Dulbecco’s Modified Eagle Medium (DMEM), 
RPMI-1640 medium, fetal bovine serum (FBS), Penicillin/Streptomycin (P/S, 50 U/mL) and 
L-glutamine (200 mM) (all of them from Gibco®) were purchased from Life Technologies 
(Thermo Fisher Scientific). MTT cell proliferation kit was, Collagenase D and DNase were 
purchased from Roche and the red blood cells (RBC) lysing buffer and Cytofix/CytopermTM 
Plus Fixation/Permeabilization Kit from BD Biosciences. Granulocyte-macrophage colony-
stimulating factor (GM-CSF) was purchased from Peprotech. IL-6 ELISA kit was purchased 
from R&D, IL-12 and TNF-α ELISA kits from Peprotech and IL-10 ELISA kits from 
BioLegend. All fluorescently labeled antibodies were obtained from BioLegend, unless 
specified otherwise. The Fc blocking antibody was purchased from BD Biosciences and 
bovine serum albumin (≥ 98%, BSA) from Sigma Aldrich. SIINFEKL OVA peptide was 
obtained from Peptides International and Matrigel® Matrix from Corning. Imject® Alum 
(Thermo Scientific) and MontanideTM ISA (kindly provided by Seppic) were prepared and 
used as described in their respective data sheets. B16-F10(OVA) melanoma cell line was a 
gift from Dr Pablo Sarobe (Centre for Applied Medical Research (CIMA), University of 
Navarra). 
Synthesis and characterisation of nanovaccines 
Hydrophobic iron oxide nanoparticles were synthetized following previously described 
method (Sun et al., 2004; Gomez Blanco et al., 2012). The IONP-filled micelles (mIONPs) 
were produced by self-assembly using a dry-film hydration method (Carion et al., 2007). 
Different IONP- to-lipid ratios were used to optimize particle size and formation yield for 
each kind of PEG-phospholipid. Typically, IONPs (1 mg) were dissolved in chloroform (500 
μL) with either DSPE- PEG(2000)-COOH (2 mg), DSPE- PEG(2000)-MAL NH2 (2.5 mg) / 
or DPPE-PEG(2000)-OMe (2 mg) plus DOTAP (0.5 mg) (Avanti Lipids). The solvent was 
left to evaporate overnight at room temperature. Any remaining solvent was removed by 
placing the dried film under vacuum for 1 hour. The film was finally heated for 30 seconds at 
80° C and hydrated by adding 1mL of nanopure water. To maximize the yield of product 
formation, IONPs combined with DPPE-PEG(2000)-OMe and DOTAP were left to hydrate 
at room temperature for 2 hours (vortexing gently every 20 minutes), prior to purification. 
The suspension was purified by centrifugation (1 cycle, 10.000 × g for 5 min), after which the 
pellet was discarded, and the supernatant was passed through a 0.45 μm PTFE syringe-filter. 
Any remaining empty micelles were removed by ultracentrifugation (3 cycles, 160.000 g for 
50 min) by discarding the supernatant. The synthesis of IONPs stabilised with poly(maleic 
anhydride-alt-1-octadecene) (PMAO) was carried out as reported previously (Moros et al., 
2010).  
In the case of the gold nanoparticles, the one-pot synthesis of PEI-modified AuNPs was 
carried out by  mixing a water solution of 1.8 kDa PEI with HAuCl4 in a 2:1 molar ratio and 
constant stirring at 90° C (Song et al., 2010; Garaikoetxea Arguinzoniz et al., 2015). The 
reaction was monitored by UV-vis over 2 h and the formation of AuNPs@PEI was confirmed 
by the appearance of a characteristic localised surface plasmon resonance band at 521 nm. 
Then, AuNPs@PEI were purified by ultrafiltration using an Amicon Ultra-4 filter device 
(MWCO 50 kDa).  
Model antigen OVA and TLR agonists were attached employing optimized PEG(2000)-
phospholipid combinations and ratios and chemistry according to their specific molecular 
features as described previously (Ruiz-de-Angulo et al., 2016). In the case of model antigen 
OVA it was incorporated into mIONPs following two different strategies: (i) by mixing the 
mIONP  (1:1 mass ratio of DPPE-mPEG(2000) and DSPE-cPEG(2000)) and the antigen 
exploiting the concept of ‘nanoparticle-protein corona’(Ruiz-de-Angulo et al., 2016), simply 
allowing the OVA protein to adsorb onto the carrier surface (IONP-OVA(abs)); or employing 
IONP micelles prepared with 2 mg of DSPE-aPEG(2000) and following a new covalent 
attachment strategy we described previously (IONP-OVA(hyd)) (Traini et al., 2019). In both 
cases, unbound OVA was removed by three cycles of ultracentrifugation (1844 × g for 5 min) 
using a NanoSep centrifugal device (Pall Life Sciences, MWCO 100 kDa) and the final 
amount of bound protein was quantified performing a bicinchoninic acid (BCA) protein assay 
(Thermo scientific) after absorbance subtraction of the same concentration of parent IONP 
micelles. To attach the nucleic acid-based TLR agonists, cationic IONP micelles were 
synthetized using 2 mg of DPPE-mPEG(2000) and 1 mg of cationic phospholipid DOTAP 
for the negatively charged CpG ODNs (Ruiz-de-Angulo et al., 2016), and polyIC and R867 
complex (Bocanegra Gondan et al., 2018). An aliquot of NP stock solution (2 µM of 
magnetite (ca. 10 mM Fe) or 90 nM of AuNPs (ca. 3 mM Au)) were mixed with the nucleic 
acid-based TLR agonists diluted in HyClone water and allowed to self-assemble overnight 
under slight stirring at room temperature (RT). Next, TLRa ligand excess was removed by 
three cycles of ultrafiltration (1844 × g for 5 min) through a NanoSep centrifugal device 
(MWCO 100 kDa) and final samples resuspended in desired water volume and stored at 4° C 
until use. In order to quantify the number of bound ligands, an aliquot of IONP-TLRa of 
stock solution was digested overnight with 0.2 M NaOH in order to hydrolyze the NPs, which 
were removed then by ultracentrifugation (369 000 × g, 40 min) to obtain a solution of free 
TLR ligands. UV−vis absorbance of this solution ( = 260 nm for nucleic acid-based TLRa 
and  = 320 nm for imiquimod) was then converted to concentration by comparison to a 
standard curve. For AuNP@PEI-pIC-R837 micelles, no further purification was done after 
TLRa addition, assuming that at the high AuNP@PEI:pIC-R837 ratio used 100 % of the 
immunostimulatory material was incorporated into the nanocarrier (Thomas and Klibanov, 
2003). 
For the transmission electron microscopy (TEM; JEOL JEM‐2011 microscope operating at 
200 kV) images, samples were prepared by depositing a drop of IONP/mIONPs solution (ca. 
0.5 mg/mL, 2 µL) onto a copper specimen grid coated with a holey carbon film and allowing 
it to dry. In the case of IONP-filled micelles, TEM grids were polarized using a Quorum 
technologies K100X glow discharge system. For IONP size determination using TEM, a 
minimum of 300 particles were measured using the Image J software. High-resolution X-ray 
photoelectron spectroscopy (XPS) measurements were carried out on Fe 2p and Fe 3p regions 
of the Fe3O4 nanoparticles to determine and confirm their elemental composition and iron 
content was measured by inductively coupled plasma atomic emission spectroscopy (ICP-
AES). Hydrodynamic diameter and zeta-potential of water soluble micelles were 
characterized with a NanoSizer (Malvern Nano‐Zs, UK) with 173° scattering angle at 25° C 
for size measurement and at 25° C with a cell drive voltage of 25 V (Smoluchowski model) 
in the case of zeta potential measurements. The results are shown as a mean of at least three 
measurements matching quality criteria.  
Nanoparticle Calculations 
Description of calculations made to obtain approximate IONP content (magnetite; Fe3O4) 
from Fe concentration measured by ICP-AES. In this study we used spherical IONPs with an 
average diameter of ca. 6.6 nm (Figure S2): 
V (IONP) = 4/3πr3 = 4/3π(3.2855 × 10-7)3 = 1.4856 × 10-19 cm3; ρ (magnetite) = 5.17 g·cm-3; 
m = ρ (magnetite) x V (IONP) = 7.6804 × 10-19 g 
moles of Fe3O4= m / MW (Fe3O4) = 7.68 × 10-19 / 231.533 = 3.3172 × 10-21 
moles of Fe = 3 x moles of Fe3O4 = 3 x 3.3172 × 10-21 = 9.9516 × 10-21 
atoms of Fe per IONP = mole Fe in IONP • NA = 9.9516 × 10-21 • 6.022 × 1023 = 5993 
Catalytic activity assay 
The peroxidase-like activity of the mIONPs was studied by monitoring the oxidation of the 
peroxidase substrates TMB and OPD in the presence of H2O2, which yields a blue ( = 652 
nm) and yellow ( = 450 nm) product respectively. The absorbance variation was monitored 
in the presence of the IONPs ([Fe] = 150 μM, for mIONPs; [Fe] = 550 μM for Ferumoxytol) 
or AuNPs ([Au] = 150 μM) nanocatalysts. The kinetic studies were performed in sodium 
acetate buffer (0.1 M, pH= 4.5, 5.5, 6.6) or PBS (0.01 M, pH = 7.4) in a total volume of 500 
μL contained in quartz cuvettes (Hellma™; path length: 10 mm). The reactions were 
monitored spectrophotometrically at room temperature in time-scan mode. The Michaelis 
Menten kinetics assays were conducted with mIONP ([Fe] = 150 μM) in sodium acetate 
buffer (pH = 4.5) and in the presence of different concentrations of H2O2 (ranging from 0.060 
to 30.3 mM) and TMB (ranging from 33.0 to 832 μM). The kinetic parameters were 














Where v is the initial velocity, Vmax is the maximal reaction velocity, [S] is the concentration 






Cell-to-cell contact co-culture  
B16-F10(OVA) melanoma cells were seeded in 96-well plates at a density of 1.8 × 105 
cells/cm2 in a volume of 200 µL. After 24 h, B16-F10(OVA) formed a 100% confluent 
monolayer and 8.5 x 104 RAW264.7 macrophage cells were seeded on top (seeding density 
of 2.7 × 105 cells/cm2) in a volume of 100 µL and allowed to adhere for 2 hours in complete 
medium (media mix ratio of RPMI-1640:DMEM = 7:1). Medium was removed, fresh RPMI-
1640 medium was added and cells were allowed to settle for 30 minutes. Finally, medium 
was removed, treatment was added, and cells were incubated over 24 h. Due to the small 
number of cells employed, each condition was performed in triplicate and cells pooled for 
further analysis. Supernatants were collected and stored at -20˚C for further cytokine 
analysis. Cell viability assessment by flow cytometry was conducted by detaching RAW 
264.7 and B16-F10(OVA) cells from the well with 100 μL of accutase® or trypsin, 
respectively. After 5 min at room temperature, the detachment solutions were neutralized 
with 100 μL of complete media. The resulting cell suspensions were washed with PBS and 
stained with 50 μL of Zombie Dye NIR diluted 1:100 in PBS over 45 min at 4° C in the dark. 
For differentiation between RAW 264.7 from B16-F10(OVA), cells were then washed with 
0.1.% BSA in PBS (and stained with Brilliant Violet-labeled anti-F4/80 antibody diluted 
1:200 in the same buffer. Finally, the cell suspensions were washed with FACS buffer (1% 
FBS in PBS) by centrifugation (3 cycles, 800 g, 4 min) and suspended in 300 μL of the same 
buffer. Positive controls for necrotic cell death were heated to 80° C for 3 min prior to 
staining. Using a NovoCyte Flow Cytometer (ACEA Biosciences), cell populations were 
gated based on the forward and side scatter parameters and the not-single events leaved out 
based on forward area and height scatter parameters (FlowJo, LCC software). Differentiation 
between cells was based on F4/80-positive fluorescent staining found in RAW 264.7 cells. 
Necrotic cell populations were gated based on Zombie Dye NIR positive fluorescent staining. 
Results were normalized to the corresponding negative controls and expressed as mean ± 
SEM. 
Transmembrane co-culture  
RAW 264.7 macrophages were co-cultured with B16-F10(OVA) melanoma cells in transwell 
plates (24-well plate) separated by a 0.4 μm pore-size membrane. RAW264.7 cells were 
seeded on the apical chamber of the transwell plate at a density of 2.5 × 105 cells/cm2 in a 
volume of 100 µL of complete DMEM medium and B16-F10(OVA) cells were seeded on the 
basolateral chamber of the well at a seeding density of 4.2 × 102 cells/cm2 in a volume of 600 
µL of complete RPMI 1640 medium. The cells were allowed to grow to 100% confluence for 
48 h (final media mix ratio RPMI-1640:DMEM = 7:1). After removing the medium, cells 
were treated over 24 h with the different formulations. Transmembrane co-cultures were 
always accompanied by mono-culture controls exposed to the corresponding treatments used 
in the co-culture. For the mono-culture controls, 8 × 104 RAW 264.7 cells were seeded on the 
bottom of a 96-well plate (seeding density of 2.5 × 105 cells/cm2) in a volume of 200 µL of 
media mix (RPMI-1640:DMEM = 7:1) and 8 × 104 B16-F10(OVA) cells were seeded on the 
bottom of a 24-well plate (seeding density of 4.2 × 102 cells/cm2) in a volume of 700 µL of 
media mix (RPMI-1640:DMEM = 7:1). Cytokine and cell viability analysis was conducted as 
described before. In this case, no anti-F4/80 staining was needed as cells were physically 
separated by the well membrane.  
Ferroptosis studies  
B16-F10(OVA) or RAW 264.7 cells were seeded at 5 × 103 cells/well (seeding density of 1.6 
× 104 cells/cm2) in flat bottom 96-well plates and cultured for 24 h in 200 µL of complete 
medium. After removing the medium, cells were treated in quadruplicate with increasing 
concentrations of erastin (0, 0.63, 1.25, 2.5 µM) diluted in 100 µL of complete medium over 
24 h. Then, and after removing erastin, cells were treated with mIONPs ([Fe] = 0.5 mM, 39 
µg/mL of magnetite) in 100 µL of complete medium. Negative controls were treated with 
complete RPMI-1640 medium only. After a 24-hour exposure, medium was removed and 50 
μL of MTT reagent in complete medium (0.5 mg/mL) was added to the cells and incubated 
for 2 h at 37° C. The supernatant was discarded and 100 μL of DMSO were added to 
solubilize the formazan crystals. Finally, the optical density of the samples was measured in a 
POLARstar Omega (BMG Labtech) microplate reader at 550 nm. Data was represented as 
the relative signal intensity to negative control, thus correlated to cell viability. Results are 
expressed as mean ± SEM. 
 
Flow cytometric analysis of lipid hydroperoxides in live cells 
B16-F10(OVA) cells were seeded at a seeding density of 4.5 x 104 cells/cm2 in 24-well plate 
and incubated in complete RPMI 1640 media for 24 h at 37 ºC, 5% CO2. Media was replaced 
with vehicle or erastin (1.25 mM; 0.63 mM; Cayman Chemical, Cambridge Bioscience, UK) 
in complete RPMI, and cells were incubated for 24 h at 37 ºC, 5% CO2. Media was then 
replaced with vehicle control (7% H2O nanopure water) or mIONPs  ([Fe] = 1 mM, 77 
µg/mL of magnetite) in complete RPMI and cells incubated for a further 24 h at 37 ºC, 5% 
CO2. Cells were then treated with Liperfluo (10 μM; Dojindo Molecular Technologies Inc) or 
DMSO vehicle control (1%) for 30 min, at 37 ºC, 5% CO2. As a positive control for lipid 
peroxides, cells were incubated with Cumene Hydroperoxide (100 μM; Sigma-Aldrich) in 
complete RPMI for 2 h at 37 ºC, 5% CO2 prior to Liperfluo addition. Cells were detached 
using 100 μl accutase® and washed once with 5 ml FACS buffer. Using a NovoCyte Flow 
Cytometer (ACEA Biosciences), cell populations were gated based on the forward and side 
scatter parameters and the not-single events leaved out based on forward area and height 
scatter parameters (FlowJo, LCC software). Differentiation between cells was based on lipid 
peroxidation-positive fluorescent staining using Liperfluo® (530 nm laser). 
Quantification of IL-6, IL-12, IL-10 and TNF-α cytokines by ELISA  
Cytokines levels were measured in cell supernatants using sandwich ELISA following 
manufactures instructions. The optical density was measured in a POLARstar Omega (BMG 
Labtech) or in a TECAN Genios Pro 96/384 microplate reader at 450-550 nm. A 4-parameter 
sigmoidal (logistic) standard curve was used to quantify the cytokine present (GraphPad 
Prism software). Results are expressed as mean ± SEM in pg/mL or ng/mL, compared to 
untreated control wells.  
Animals  
Animals were cared for and handled in compliance with the Guidelines for Accommodation 
and Care of Animals (European Convention for the Protection of Vertebrate Animals Used 
for Experimental and Other Scientific Purposes) and internal guidelines, and all the 
experimental procedures were approved by the appropriate local authorities. All animals were 
housed in ventilated cages and fed on a standard diet ad libitum. 
Radiolabelling of nanovaccines and SPECT/CT studies  
IONVs were radiolabelled adopting synthesis-free method as previously described for related 
nanovaccines (Ščasnár and van Lier, 1993; Ruiz-de-Angulo et al., 2016). In brief, after 
purification of purchased gallium-67 (CuriumTM, specific activity =1.4 TBq/μmol), 50 µL of 
IONPs (ca. 1 µM of magnetite) were mixed with 100 µL of 67GaCl3 (ca. 37 MBq) and diluted 
up to 500 µL in acetate buffer (pH = 3.8 ± 0.1). Reaction was incubated over 30 min at 70° C 
and unbound gallium-67 was removed by two cycles of ultrafiltration (6708g for 10 min) 
through Amicon Ultracel (MWCO = 100 kDa) centrifugal devices, after what the retentate 
was recovered in PBS (10 mM), ready to be injected. In order to assess the stability of the 
label, 67Ga-IONP-TLRa/OVA micelles were incubated with a large excess of DOTA chelator 
as competitor for gallium atoms (106 moles of DOTA per mole of nanoparticle) at 37° C. At 
different time points, the samples were filtered again to separate radiolabelled micelles from 
DOTA-67Ga complex. Depending on the activity, samples were measured using a CRC-25R 
dose calibrator (Capintec, USA) or a 2470 WIZARD2 Automatic Gamma Counter 
(PerkinElmer). For in vivo imaging studies, tumour bearing C57BL/6 female mice (6-8 weeks 
old) were subcutaneously administered with 40 µL of 67Ga-IONP-TLRa/OVA micelles (all 
injection ranged from 35 to 45 MBq). With the mouse under isoflurane anaesthesia (1.5−2% 
in oxygen), whole-body SPECT/CT scans were acquired at 3, 24 and 48 h after the injection 
using an eXplore speCZT CT scanner and an 8-slit collimator with a field of view of 32 and 
78 mm in the transaxial and axial directions, respectively. With the full ring detector, 360° of 
data were acquired by rotating the collimator 45° (45 steps, 1°/step). Data were collected in 
an energy acquisition window from 125−150 keV to 84−102 keV and acquisition times from 
60 min (80 s/step) to 45 min (60 s/step). The CT acquisition consisted of 220 views were 
acquired in 0.88° increments around the animal with 16 ms exposure per view. The X-ray 
tube settings were 70 kV and 32 mA. The SPECT images were reconstructed using the 
OSEM iterative algorithm (5 and 15 subsets, 3 and 5 iterations) into 128 × 128 × 32 array 
with a voxel size of 0.4 × 0.4 × 2.46 mm, and were not corrected for scatter and attenuation. 
The CT images were reconstructed using a cone beam filtered back-projection Feldkamp 
algorithm into 437 × 437 × 523 array with a voxel size of 0.2 × 0.2 × 0.2 mm. During image 
acquisition, mice were kept normothermic by the use of a heating blanket (Homeothermic 
Blanket Control Unit; Bruker BioSpin GmbH, Karlsruhe, Germany). After each SPECT scan, 
CT acquisitions were performed to provide anatomical information on each animal. For the 
quantification of SPECT images, PMOD image analysis software (PMOD Technologies Ltd, 
Zurich, Switzerland) was employed. Volumes of interest (VOIs) were drawn in major organs 
(namely, brain, lungs, heart, liver, kidneys, bladder and tumour) and those lymph nodes 
visible on the SPECT images, and the concentration of radioactivity was determined as 
counts per second per cubic centimetre (cps/cm3). Values were normalised to the total amount 
of radioactivity present in the animal at t = 3 h. This value was determined by drawing a VOI 
on the whole animal. Values were finally expressed as percentage of injected dose (% ID) per 
cm3. At the end of the scanning procedure, animals were sacrificed, and the organs of interest 
were removed for further ex vivo SPECT/CT imaging applying the same conditions of the in 
vivo images. Analysis of the injected dose percentage per gram of organ was performed by 
measuring their activity with the Gamma Counter.  
Radiolabelling of immune checkpoint antibodies and immune-PET studies   
For the detection of PD-L1 and OX40 expression in vivo, antibodies were radiolabeled with 
89Zr, which was produced in-house as [89Zr]ZrC2O4 as previously reported (Zhang et al., 
2020). First, Abs were functionalised with the chelator. With that aim, the corresponding 
antibody was diluted with PBS to a final concentration of 2 mg/mL, the pH was adjusted to 
8.7-9.0 with 0.1 M sodium carbonate and 5 equivalents of p-NCS-Bz-DFO (p-
isothiocyanatobenzyl-desferrioxamine) were added. After 45 min incubation at 37 ºC the Abs 
were purified by spin filtration (12 000 rpm, 100 kDa, 6 min) and washed three times with 
PBS. The final protein concentration was determined by NanoDrop®. Radiolabelling of 
mAb-DFO with 89Zr was performed by incubation with [89Zr]ZrC2O4 in a 1 M oxalic acid 
solution. Therefore 50 or 500 µl of 1 M oxalic acid containing 89Zr (ca. 37 MBq) were 
neutralized with 2 M sodium carbonate, 500 µg mAb was added and the volume adjusted to 
0.5 or 1.0 mL with 0.5 M HEPES buffer. After 1 h incubation at room temperature the 
antibodies were purified by size exclusion chromatography (NAP5® or PD10®) and PBS. 
The incubation and purification were monitored by iTLC. The radiochemical yield was 35-
80%, depending on the batch of 89Zr. PET imaging studies were conducted using PET in 
combination with computerized tomography (CT), using the β- and X-cube micro system of 
Molecubes. Static whole-body images (1 bed) were acquired in a 511 keV ± 30 % energetic 
window, with a total acquisition time of 10 min. PET images were analysed using PMOD 
image analysis software (PMOD Technologies Ltd, Zurich, Switzerland).  
Tumour experiments  
For the prophylactic approach, C57BL/6 female mice (6-8 weeks old) were immunized 
subcutaneously on day 0 and 14. One week after second immunization (day 21), 3 × 105 B16-
F10(OVA) cells mixed with Matrigel® Matrix (volume ratio of 2:1) were implanted in the 
right back of mice. On the other hand, in the therapeutic strategy mice were subcutaneously 
injected with the melanoma cancer cells and then treated on days 7, 10 and 13 after tumor 
challenge. In order to compare IONP-filled micelles with Ferumoxytol, B16-F10(OVA) 
cancer cells were co-administered together with the treatment. Finally, when immune 
checkpoint inhibitors were used, therapy regime was slightly changed: nanovaccines were 
subcutaneously injected on days 4, 11 and 18 after tumor implantation and, 1 and 4 days after 
each treatment, monoclonal antibodies blocking PD-L1 (100 µg, intraperitoneal) and/or 
activating OX40 (10 µg, intratumoral) were administered. In all cases, animals were 
monitored for tumor growth every two days using an electronic caliper 779A series (starrett). 
Criteria for humane endpoint included tumors greater than 1.5 cm diameter or ulceration. 
Tissue processing protocols 
Bone marrow derived dendritic cell (BMDC) primary culture. C57BL/6 female mice (6−12 
weeks old) were sacrificed by cervical dislocation and intact femurs and tibiae of hind limbs 
were removed. Bones were washed in cold PBS (10 mM) and bone marrow was flushed with 
the same buffer using a syringe as described previously (Lutz et al., 1999). After the 
erythrocytes were lysed, the cells were washed and resuspended in RPMI-1640 supplemented 
with penicillin (100 μg/mL), Streptomycin (100 μg/ mL), L-glutamine (2 mM) and heat 
inactivated FBS (10%). On day zero cells were plated at a concentration of 2 × 106 cells per 
100 mm bacteriological Petri dish (Falcon) in 10 mL of media supplemented with 20 ng/mL 
of murine GM-CSF (Peprotech) and maintained in a humidified incubator with 37° C and 5% 
CO2. On day 3, 10 mL of complete RPMI media containing GM-CSF (20 ng/mL) was added 
to each Petri dish. On day 6, half of the supernatant was collected, centrifuged and cell pellet 
resuspended in 10 mL of fresh complete RPMI with GM-CSF (10 ng/mL) and added again to 
each Petri dish. Finally, on day 8 cells were harvested for further analysis. 
Purification of Peripheral Blood Cells. To analyse the circulating T cells immune response, 
blood was taken (100 μL) via the facial vein and diluted up to 4 mL in cold PBS (10 mM). 
After centrifugation (1028g, 5 min at 4° C), the pellet was resuspended in 5 mL of RBC lysis 
buffer and incubated at room temperature for 5 min while vortexing vigorously. The lysis 
was quenched by addition of 8 mL of 5% FBS in PBS (10 mM) and mixture was washed 
twice, ready for further analysis.  
Splenocytes, lymphocytes and tumour-infiltrating immune primary cultures. Spleens, TDLN 
and tumour tissue were perfused with tissue dissociating mix (3, 2.5 and 5 mL of 
collagenase/DNase I in RPMI-1640, respectively), cut into small pieces and incubated for 30 
min at RT. After stopping the reaction with 500 mM EDTA, organs were smashed with the 
plunger of a syringe and resulted cell suspension collected into falcons after removing big 
tissue clamps. Red blood cell lysis was performed by adding RBC lysis buffer to cell pellets 
and incubating at RT (2 mL over 5 min for spleens and 1 mL over 1 min for tumours). Cells 
were washed twice with 8 mL of 5% FBS in PBS (10 mM) and resuspended in 2 mL of 
complete RPMI-1640 ready to use. 
In vitro experiments with dendritic cells  
The study of DCs activation when incubated with IONP-filled micelles or TLRas was 
conducted using primary culture of bone marrow derived dendritic cells (BMDCs). 
Differentiated BMDCs were resuspended in complete RPMI-1640 and plated at a final 
concentration of 2 × 105 cells/well (0.1mL/well) in round-bottom (activation markers) or flat-
bottom (cytokines) 96-well plates. Each formulation was diluted accordingly in media and 
added to cells (0.1 mL), in triplicate. 24 h after, supernatants were harvested for further 
cytokine analysis. Cell viability of BMDCs was measured using the MTT assay as previously 
described. To analyze the activation markers on DC surface, cells were washed twice with 
PBS buffer and stained with Alexa Fluor 488-labeled anti-CD11c, PerCP-Cy5.5-labeled anti-
IA/IE, Brilliant Violet 421-labeled anti-CD80, PE-labeled anti-CD86, and APC-labeled anti-
PD-L1 antibodies. Using a FACS Canto II flow cytometer (BD Bioscience), cells were 
electronically gated based on the forward and side scatter parameter and the not-single events 
leaved out based on forward area and height scatter parameters (FlowJo, LCC software). DCs 
were gated based on positive staining for CD11 population marker, where the relative mean 
fluorescence intensity (MFI) of each marker was analyzed. Isotype controls were included in 
each assay and are not showed in the figures for clarity purposes. Experiment was conducted 
three times. 
Assessing immune responses in vivo  
In order to study the immune response after immunization and tumor challenge, C57BL/6 
female mice were administered subcutaneously with 5 µg of OVA, 12 µg of polyIC and 4 µg 
of R837 alone or in combination with IONP micelles (78 µg of magnetite) on day 0 and 14. 
21 days after first immunization, mice were challenged with 3 × 105 B16-F10(OVA) 
melanoma cells and, after 63 days (84 days after the beginning of the experiment) re-
challenged with another 3 × 105 B16-F10(OVA) tumor cells. Mice were culled by cervical 
dislocation 128 days after first administration and blood samples and spleens harvested for 
the analysis of the generated immune response. Both splenocytes and blood cells were 
analyzed for SIINFEKL-specific CD8+ T cells and effector memory CD8+ T cells. 1 × 106 
cells were plated in round-bottom 96-well plates and washed with 5% FBS in PBS (10 mM). 
Cells were stained with Brilliant Violet 421-labeled anti-CD3, PE.Cy7-labeled anti-CD8, 
APC-labeled anti-CD44, FITC-labeled anti-CD62L and PE-labeled H-2kb-OVA257-264 
dextramer (Immudex). SIINFEKL specific cell percentage was analyzed in the CD8+ T cell 
population (CD3+ and CD8+ double positive) or in the effector memory CD8+ T cell 
population (inside CD3+ and CD8+ double positive population, cells showing a phenotype of 
CD44high and CD62Llow). In order to analyze the intracellular cytokine production by flow 
cytometry, 1 x 106 splenocytes were seeded also in round-bottom 96-well plates but diluted in 
complete RPMI media (0.1 mL/well). Another 0.1 mL were added per well containing the 
BD GolgiStop™ Protein Transport Inhibitor (1.4 µg/mL of Monensin), the PE-labelled anti-
CD107a antibody (LAMP-1 protein) and 10 μg/mL of SIINFEKL diluted in media. After 5 h 
incubation at 37° C, cells were washed and stained with Brilliant Violet 421-labeled anti-
CD3, FITC-labeled anti-CD8 and Brilliant Violet 510-labeled anti-CD4. Then cells were 
fixed and permeabilized using the commercially available BD Cytofix/Cytoperm fixation and 
permeabilisation kit and intracellularly stained with APC-labeled anti-IFN-y and PE.Cy7-
labeled anti-TNF-α. Cells were gated based on double positive for CD3 and CD8 markers, 
excluding CD4+ cells and vice versa. Intracellular cytokines and degranulation marker were 
analyzed in CD3+CD4+ or CD3+CD8+ double positive cell populations. Isotype controls were 
included and were not showed in the figures for clarity purposes. Results were expressed as 
mean ± SEM of at least 3 mice per group of immunization and compared to unstimulated 
wells.  
Analysis of immune cells phenotype in vivo  
For the study of OX40 positive immune cells in vivo C57BL/6 female mice were injected 
with 3 × 105 melanoma cells in the back and, 8 days later, animals were sacrificed and organs 
of interest harvested (see Supplemental Information for tissue processing description). 1 × 
106 cells were plated in round-bottom 96-well plates and washed with FACS buffer. Cells 
were stained with Brilliant Violet 421-labeled anti-CD3, Brilliant Violet 510-labeled anti-
CD4, PE.Cy7-labeled anti-CD8, APC-labeled anti-CD44, FITC-labeled anti-CD25 and 
PerCP-Cy5.5-labeled anti-OX40. Expression of OX40 marker was analyzed in CD3+ and 
CD4+ T cells. CD44 and CD25 activation markers were used to analyze the phenotypic 
differences between OX40 positive and negatives T cells. The analysis of PD-L1 expression 
in B16-F10(OVA) melanoma cells was analysed by staining the cells with APC-labeled anti-
PD-L1.  
Statistical analysis  
Data presented as mean ± SEM. The differences between the control and the experimental 
groups were assessed using two-tailed unpaired Student’s t tests and the differences among 
groups > 2 by one-way ANOVA (GraphPad Prism, GraphPad Software, La Jolla, CA). 
Statistical significance was set at *p < 0.05; **p < 0.01; #p < 0.001, as indicated in the figure 
legends. All in vivo experiments were repeated at least twice with a minimum of five mice 
per group and the in vitro studies a minimum of three times.  
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Supplemental data items 
 
Figure S1. Statistical analysis of tumour growth curves. * P < 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001 by one-way ANOVA followed by Tukey’s test for days where all 
animals were still alive (A) and by two-tailed unpaired Student's t-test for days where any 
group was already missing (B-F). G) Linear regression of each tumour growth curve showed 
in Figure 1D was performed and the mean value of the slopes of each experimental group 














































































































































































































































































































































Figure S2. Characterization of hydrophobic IONPs employed in this work. A) 
Representative TEM images and size distribution of more than 300 IONPs. XPS spectra of B) 
Fe 2p and C) Fe 3p. Related to Figures 2-8 and Figure 10.   
 
Figure S3. Characterization and biofunctionalization of magnetite-filled micelles. A-C) 
Representative TEM images of iron oxide-based micelles: A) DPPE-mPEG(2000):DOTAP 
stabilized mIONPs and PEG-PL-coated for OVA B) absorption (DSPE-cPEG(2000) with 
COOH end groups) and C) covalent anchoring by hydrazone linkages (DSPE-aPEG(2000) 
with NH2 end groups). D-I) Hydrodynamic size distribution and zeta potential of 
functionalized micelles measured by DLS. Related to Figures 2-8 and Figure 10. 
 
 
Figure S4. Hydrodynamic size characterization by DLS of DPPE-mPEG(2000):DOTAP 
stabilized IONP functionalized with increasing amounts of pIC (mIONP-pIC), just after 
synthesis and after purification at days 0 and 7 stored at 4° C: A) particle size mean by 
intensity and B) polydispersity index (PDI); C) particle size mean by number after 
purification. Data are presented as an average of three readouts. D) Absorbance spectra 
comparison between mIONP-DOTAP and mIONP-pIC after purification, indicating the 
effective capture of pIC. E) Typical pIC absorption spectra. F) pIC absorption peaks after 
digestion in basic environment (λ = 260 nm) and G) linear regression made to determine the 
H) pIC capture yield in the mIONPs surface (%). Related to Figures 2-8 and Figure 10. 
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Figure S5. Characterization of DPPE-mPEG(2000):DOTAP-coated IONP micelles 
functionalized with pIC and R837 (mIONP-pIC-R837). A-C) Hydrodynamic size 
characterization by DLS of mIONP-pIC-R837 micelles, after synthesis and purification at 
days 0, 7 and 14 in PBS at 4° C: A) particle size mean by intensity, B) polydispersity index 
(PDI), and C) particle size mean by number. Data are presented as an average of three 
readouts. Absorbance spectra comparison between D) mIONP-DOTAP and mIONP-pIC, E) 
mIONP-pIC-R837 and mIONP-pIC, and F) and mIONP-pIC-R837 and mIONP after 
purification, indicating the effective capture of both pIC (31 µg/mL) and R837 (5 µg/mL). 
Final capture yield (%) of G) pIC (measured upon basic digestion) and H) R837 (measured at 
λ = 320 nm prior to digestion). Related to Figures 2-6, Figure 8 and Figure 10. 
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Figure S6. Dynamics of 67Ga-labeled mIONP-CpG ODN nanovaccine over the different 
experimental time points. Radiolabeled mIONP-CpG ODNs (23.6 μg of magnetite, 43.4 
MBq) were injected into the hock of tumour bearing mice and in vivo acquired images were 
analysed using PMOD software, at 3, 24 and 48 h after administration. Related to Figure 2. 
 
Figure S7. Biodistribution analysis of differently functionalized nanovaccines 
administered subcutaneously in tumour bearing mice. A) mIONP-pIC-R837 micelles 
administered peritumorally (4.68 µg of magnetite, 34.8 MBq) and analyzed after 24 h; B) 
mIONP-CpG micelles injected in the right flank (23.6 µg of magnetite, 42.2 MBq, 48 h); and 
C) mIONP-OVA micelles injected in the right hind limb (hock, 15.6 µg of magnetite, 40.7 
MBq, 48h). bLN, brachial LN; aLN, axillary LN; iLN, iliac LN; sLN, sciatic LN; inLN, 

















































































































































































































































































































































































mIONP-TLRa – 24 h
A
 
Figure S8. Incorporation of TLRa/OVA into IONP-filled micelles enhances the 
therapeutic outcome of antigen/adjuvant immunotherapy. C57BL/6 mice (n = 5) were 
treated on day 7, 10 and 13 after B16-F10(OVA) cells injection in the right back. Animals 
were subcutaneously administered (hock) with 10 µg of OVA in combination with adjuvants 
suitable for human vaccines (Alum, MontanideTM (1:1 volume ratio with antigen solution)) 
and either with A-C) pIC-R837 (4 and 2 µg, respectively) or D-F) CpG ODNs (10 µg) loaded 
into IONP-filled micelles (119 µg magnetite). A, D) Average tumour growth curves; B, E) 
Kaplan-Meier survival curves; and C, F) animal body weight change over the experiment. 
Arrows indicate the days of therapy administration. Data are showed as mean ± SEM. * P < 
0.05, ** P < 0.01 by two-tailed unpaired Student's t-test (A, D) and by Log-rank (Mantel-
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Figure S9. Long-term adaptive immune response elicited by nanovaccines. C57BL/6 
female mice (n = 5) were subcutaneously immunized with 5 µg of OVA, 12 µg of polyIC, 4 
µg of R837 alone or adsorbed to mIONPs on day 0 and 14 and, on day 21 were challenged 
with 3 x 105 B16-F10(OVA) cells. On day 84 after first immunization, animals were 
rechallenged with melanoma cells in the contralateral side. Six weeks later, mice were 
sacrificed, and blood and spleens were collected for further immune analysis. A) Effector 
(TEM) and central memory (TCM) CD8+ T cell percentages in spleen. SIINFEKL-specific (B, 
C) CD8+ and (D, E) TEM cells in (B, D) spleen and (C, E) blood. (F-I) Intracellular IFN-γ and 
TNF-α production and CD107a expression in (F, G) CD8+ and (H, I) CD4+ T cells after 5 h 
of incubation with 10 µg/mL of SIINFEKL peptide. * P<0.05, **P<0.01, by one-way 
ANOVA followed by Tukey’s test. Related Figure 3. 
 
 
Figure S10. Changes in size of the micelles modified drastically the biodistribution of 
the vaccine. C57BL/6 mice (n = 2) were administered with mIONP-big micelles (9.2 µg of 
magnetite, 2.65 MBq) subcutaneously in the left hock. SPECT/CT images of representative 
mouse A) 3 h and B) 24 h after injection. C) Photograph of selected harvested organs, D) 
SPECT/CT images of the extracted organs and E) biodistribution expressed as injected dose 
percentage per gram of tissue. bLN, brachial LN; aLN, axillary LN; Lu, lungs; L, liver; S, 
spleen; K, kidneys; iliac LN; sLN, sciatic LN; inLN, inguinal LN; pLN, popliteal LN; 

































































































































































Figure S11. Characterization of PEI-capped AuNP micelles. A) UV-vis spectra of the 
solutions of HAuCl4 and 1.8 kDa PEI at different stages of the synthesis in water and B) the 
spectrum showing the surface plasmon resonance band at 521 nm. C) Representative TEM 
images, D) size distribution of more than 300 NPs, and E) hydrodynamic diameter analyzed 
by DLS. F-H) AuNP@PEI-TLRa system characterization showing F) a representative TEM 
image, G) hydrodynamic diameter measured by DLS and H) zeta potential values before and 
after functionalization with TLRas. Related to Figure 6. 
  
Figure S12. Statistical analysis of tumour growth curves. * P < 0.05, ** P < 0.01, *** P < 
0.001 by two-tailed unpaired Student's t-test at days A) 13, B) 15, and C) 22 after tumour 















































































































































































































































































































































Figure S13. Melanoma B16-F10(OVA) and RAW 264.7 macrophage cells co-culture 
(transmembrane and cell-to-cell contact) experiments. A) Schematic representation of 
B16-F10(OVA) and RAW 264.7 transmembrane co-culture set-up. Comparison of B) B16-
F10(OVA) and C) RAW 264.7 cell viability in mono-culture (M, solid bars) or 
transmembrane co-culture (C, striped bars), represented as subtraction from normalized 
necrotic cell death triggered upon treatment. Cytokine levels elicited upon treatment under 
cell-to-cell contact co-culture approaches for D) TNF-α and E) IL-10. 77 µg/mL magnetite = 
1 mM of Fe. Data are shown as mean ± SEM (n =3). * P < 0.05, ** P < 0.01, **** P < 
0.0001 by B, C) two-way ANOVA followed by Tukey’s test and D, E) one-way ANOVA 














































































































































































































































Figure S14. Cell gating strategy employed over this work. A) PD-L1 expression in B16-
F10(OVA) mouse melanoma cells analyzed by flow cytometry. B) Cell viability as necrotic 
development in cell-to-cell co-cultures of B16-F10(OVA) melanoma and RAW 264.7 cells; 
C) DCs population defined as CD11c+ cells; T cells gating for D) immune response analysis 
and E) tumour-infiltrating immune cells analysis. Related to Figures 1, 3, 6, 8, 9 and 10. 
